We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Benign Hematology

Journal Scan / Research · December 07, 2020

Second Primary Malignancy in Myelofibrosis Patients Treated With Ruxolitinib

British Journal of Haematology


Additional Info

British Journal of Haematology
Second Primary Malignancy in Myelofibrosis Patients Treated With Ruxolitinib
Br. J. Haematol 2020 Nov 21;[EPub Ahead of Print], N Polverelli, EM Elli, E Abruzzese, GA Palumbo, G Benevolo, M Tiribelli, M Bonifacio, A Tieghi, G Caocci, M D'Adda, M Bergamaschi, G Binotto, FH Heidel, F Cavazzini, M Crugnola, N Pugliese, C Bosi, A Isidori, D Bartoletti, G Auteri, R Latagliata, L Gandolfi, B Martino, L Scaffidi, D Cattaneo, F D'Amore, MM Trawinska, R Stella, U Markovic, L Catani, F Pane, A Cuneo, M Krampera, G Semenzato, RM Lemoli, N Vianelli, M Breccia, D Russo, M Cavo, A Iurlo, F Palandri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading